Genmab announces new results from Phase 1b/2 EPCORE NHL-2 trial

Genmab (GMAB) A/S announced new results from the Phase 1b/2 EPCORE NHL-2 trial evaluating fixed-duration epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, plus lenalidomide + rituximab in adult patients with relapsed or refractory follicular lymphoma. The results demonstrated an overall response rate of 96% and a complete response rate of 87% among 111 patients after a median follow-up of two years. Additionally, the study showed an estimated 21-month progression-free survival rate of 80% and a two-year overall survival rate of 90%. The data were shared during an oral presentation at the 66th Annual Meeting and Exposition of the American Society of Hematology. Additional data from the study showed an estimated 89% of complete responders to the combination therapy remained in CR at 18 months. With the majority of patients being enrolled and treated during the global COVID-19 pandemic, COVID-19 was reported in 57 percent of patients and led to epcoritamab discontinuation in 13 percent of patients. Five cases of COVID-19 led to fatal treatment-emergent adverse events. All CRS cases resolved. One case of immune effector cell-associated neurotoxicity syndrome was reported. The CRS and ICANS cases did not lead to treatment discontinuation.